TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Oct 17, 2022 09:48 JST
Source:
EC Healthcare
EC Healthcare expects a record-high semi-annual sales volume in first half of FY23 of no less than HK$1.8 billion, Represents no less than 17% Y-o-Y increase
Demonstrate a Notable Recovery Trend and Moving Towards New Normal
HONG KONG, Oct 17, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group expects to achieve a record-high semi-annual sales volume from April to September 2022 (the "Reporting Period").
The demand on medical services provided by the Group remains strong and the Group's business demonstrate resilience and momentum backed by the Group's diversified business. The Board expects the Group to achieve a record-high semi-annual overall sales volume of no less than HK$1.8 billion for the Reporting Period, representing a no less than 17% y-o-y increase. The Group expects to achieve a no less than 30% y-o-y increase for medical services sales volume. Sales volume of other services rose by no less than 95% y-o-y, mainly driven by the acquisition of veterinary businesses.
Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, EC Healthcare is always committed to building a diversified healthcare ecosystem to maximize customers' lifetime value. Hong Kong resident now progressively building a herd immunity barrier with a population the cumulative number of reported cases of 5th wave of COVID-19 has reached over 181 million, population completed the third vaccine dose was at approximately 80.2% as of 13 October 2022. The steady recovery in local consumer sentiment is expected to benefit the Group's business. Looking ahead, the Group is optimistic about its business development as the Hong Kong government's pandemic policy stance is heading towards "Normalization" and recently further relaxed quarantine arrangements for inbound travelers, further boosting the market sentiment. The Group will continue to expand its businesses through organic growth as well as mergers and acquisitions, leveraging investment in IT, brand and service to enrich the Group's enclosed diversified ecosystem. The Group will further enhance the resilience and ability to resist economic cyclical changes and further consolidate the healthcare market."
About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.
The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.
*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021
For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Tim Tin / Sophia Wu
Tel: (852) 2136 6952 / 2169 0467 / 3920 7654 / 3920 7645
Fax: (852) 3170 6606
Email:
ech@iprogilvy.com
Source: EC Healthcare
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Kerry Logistics Network Teams Up with EC Healthcare to Provide a Full Suite of Integrated Medical Logistics Management Services
November 27 2023 11:15 JST
EC Healthcare Received "Institutional Investor" 2023 Multiple Awards in All-Asia Executive Team Rankings
June 21 2023 18:50 JST
EC Healthcare Signs Sustainability-Linked Syndicated Facility, A Ground-breaking Achievement in Hong Kong Healthcare Industry
May 10 2023 11:52 JST
Leading Aesthetic Medical Devices and Consumables Distributor in Hong Kong Consolidating Quality Resources and Leading the Industry to Stay Ahead
April 03 2023 20:39 JST
EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong
March 24 2023 17:21 JST
EC Healthcare Opened the First Organic Flagship Veterinary Hospital in Hong Kong
March 06 2023 15:50 JST
EC Healthcare Announced Strategic Alliance with Prudential
February 13 2023 19:09 JST
EC Healthcare Expects Third Quarter FY23 Sales Volume to Increase no less than 8% YoY
January 20 2023 19:31 JST
EC Healthcare wins "Best in Healthcare Sector" at IR Magazine's Greater China Awards 2022
December 14 2022 21:38 JST
EC Healthcare Announces FY2022/23 Interim Results, Revenue Increased 31.1% YoY Mainly Driven by Medical Services
November 24 2022 13:02 JST
More Press release >>
Latest Press Release
Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into "Next-generation Convenience Store"
Sep 20, 2024 18:02 JST
Hitachi Rail is innovating and delivering transformative 5G digital signalling
Sep 20, 2024 16:47 JST
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sep 20, 2024 15:00 JST
Honda to Relocate the Base of its Rugby Team Activities
Sep 19, 2024 15:05 JST
Renewal of Compact CO2 Capture System "CO2MPACT(TM)" Series
Sep 19, 2024 14:35 JST
The world's first commercial copper die-cast rotor for railway traction motors
Sep 19, 2024 13:57 JST
NEC Secures Fifth Consecutive Worldwide Partner of the Year Award from Juniper Networks
Sep 19, 2024 13:08 JST
Fujitsu and Stellar Science Foundation form partnership agreement to foster innovation by supporting young researchers
Sep 19, 2024 10:31 JST
Approval in Principle (AiP) Acquired from Two Classification Societies for Low-Pressure Type Liquefied CO2 Carriers undergoing Pursuit of Standardization toward Realization of Large-Scale International Transportation from 2028 onwards
Sep 18, 2024 18:02 JST
Europe's First Post-Combustion Carbon Capture Plant Starts Operation with MHI Technology as part of the Ravenna CCS Project, Phase 1
Sep 18, 2024 17:24 JST
Eutelsat and Mitsubishi Heavy Industries Reach Agreement for Multiple Launches
Sep 18, 2024 17:19 JST
NEC Orchestrating Future Fund invests in Sakana AI to promote development of generative AI
Sep 18, 2024 13:02 JST
IHI, Fujitsu, and Mizuho Bank form agreement to launch joint business venture to provide total support scheme for J-Credit
Sep 18, 2024 11:28 JST
JCB and Azer Turk Bank launch JCB merchant acquiring operations across the Republic of Azerbaijan
Sep 17, 2024 17:00 JST
Fuji frustration for TOYOTA GAZOO Racing
Sep 17, 2024 15:01 JST
Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner
Sep 17, 2024 14:30 JST
Japan International Aerospace Exhibition 2024: Japan's largest comprehensive aerospace industry exhibition
Sep 17, 2024 12:00 JST
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sep 17, 2024 10:08 JST
DENSO Wins Medals at 47th WorldSkills Competition
Sep 16, 2024 19:54 JST
Mitsubishi Corporation and ExxonMobil sign Project Framework Agreement to advance world's largest low-carbon hydrogen project
Sep 13, 2024 20:07 JST
More Latest Release >>